Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Neurodegenerative, Oncology, and Metabolism Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALDH2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| WT Antigen | ALDH2 Wild-Type Recombinant Protein Full-length, N-terminal His or GST tag options. Sequence Verified. High Purity (>95%). Endotoxin <1 EU/μg. Theoretical MW confirmed. NADH-generation activity tested. |
View ALDH2 Products |
| Mutant Antigen (ALDH2*2) | ALDH2 E504K (E487K) Mutant Protein Clinically prevalent East Asian variant for activator screening. Sequence Verified. Theoretical MW confirmed. High purity (>95%), Endotoxin <1 EU/μg. Directly comparable to WT in NADH-coupled kinetic assays. |
View ALDH2 Products |
| Gene Delivery | ALDH2 Promise-ORF / Lentivirus WT and E504K full-length ORF with mitochondrial targeting sequence (MTS). CMV promoter, Puromycin selection. For stable cell line construction in HEK293, H9C2, or HepG2. |
View ALDH2 Products |
| Benchmark Control | Research Grade Anti-ALDH2 Antibody (Clone 2E5) For Western Blot, ELISA, and immunofluorescence validation. Sequence defined. |
View ALDH2 Products |
| Validator | ALDH2 siRNA Set Gene-specific knockdown for assay specificity verification and target engagement control. Three independent target sequences provided. |
View ALDH2 Products |
| Related Target A | ALDH1A1 Stem cell marker; critical for isoform selectivity counter-screening. Primary off-target liability for inhibitor development. |
View ALDH1A1 Products |
| Related Target B | ALDH3A1 Oxidative stress response; corneal isoform; essential for ALDH family cross-reactivity panel. |
View ALDH3A1 Products |
| Related Target C | ADH1B Upstream alcohol metabolism partner; synergistic pathway analysis. |
View ADH1B Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (vs ALDH1A1/ALDH3A1 off-targets) | Homolog panel proteins (ALDH1A1, ALDH2, ALDH3A1) >95% purity; strict mass spec and Theoretical MW verification for accurate counter-screening. |
| ALDH2*2 Mutant Activation Screening | Matched WT and E504K mutant proteins with endotoxin control; ready for NADH fluorescence/absorbance kinetic assays. Direct comparison of Vmax and Km(NAD+). |
| Mitochondrial Localization & Cell-Based Validation | Lentivirus with native MTS for stable cell line generation; preserves physiological folding and mitochondrial targeting. Suitable for cellular enzyme activity and thermal shift assays. |
| Activator Binding Confirmation | High-concentration protein (5-10 mg/mL) suitable for thermal shift assays (DSF) and SPR. Low-viscosity buffer (50 mM PB, pH 7.4, 10% Glycerol) supports HTS. |
| Assay Specificity & False Positive Control | ALDH2 siRNA set included for target knockdown verification; three independent sequences minimize off-target effects. |
| Standardization of Enzyme Assays | High-purity, endotoxin-controlled recombinant proteins ensuring consistent baseline kinetics across batches. |
Live ALDH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Cardioprotection Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ALDH2-targeted therapeutics is intensifying, with major players shifting focus from traditional alcohol metabolism management to precision cardiovascular protection, neurodegenerative disorders (Alzheimer's, Parkinson's), and oncology adjuvants. First-generation small-molecule activators (Alda-1 analogs) demonstrate cardioprotective efficacy in preclinical models for ischemia/reperfusion injury. The next wave of R&D explicitly targets:
- Mutant-selective activators for the ALDH2*2 (E504K/E487K) allele prevalent in East Asian populations (~30-50% carrier frequency),
- Isoform-selective inhibitors for cancer stem cell eradication and overcoming chemoresistance in solid tumors,
- Gene therapy (AAV/lentivirus) for inherited ALDH2 deficiency, and
- Prodrug activation strategies to address chemotherapy resistance.
The clinical landscape is shifting from enzyme replacement to precision small-molecule modalities, with increasing focus on restoring mutant enzyme function and achieving >100-fold selectivity over ALDH1A1/3A1 to avoid hematopoietic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activator | Stanford University, Foresee Pharmaceuticals, Cytomedix, Asian Biotechs | Ischemic Heart Disease, Heart Failure, Peripheral Arterial Disease (PAD), Alcohol Flush Syndrome, Neurodegenerative Disorders | WT vs E504K Mutant Enzyme Kinetics (Need high-purity mutant & WT proteins) |
| Isoform-Selective Inhibitor | NCI, Academic Consortia, NIAAA, Oncology Biotechs | Solid Tumors (Stemness), Chemoresistance, Alcohol Use Disorder | Selectivity Panel (Need ALDH1A1/ALDH3A1 homologs for counter-screening) |
| Gene Therapy (AAV/Lentivirus) | Early Stage Academic | Inherited ALDH2 Deficiency, Genetic ALDH2*2 | Cell Line Validation (Need ORF lentivirus for overexpression models and mitochondrial localization) |
| Prodrug Activation | Oncology Focused Biotechs | Chemotherapy Resistance | Cellular Metabolism Assay (Need stable overexpression lines with WT or mutant ALDH2) |
Key Mutations & Genetic Variants
Based on current knowledge, ALDH2 carries clinically important mutations:
- rs671 (ALDH2*2): E504K (also referred to as E487K). Drastic reduction of enzyme activity; prevalent in East Asian populations.
- rs1062136: Associated with subtle functional modulation.
- rs769724893 (ALDH2*3): Rare variant with potential enzymatic impact.
TarMart offers both WT and ALDH2*2 recombinant proteins plus ORF lentivirus to support variant-specific drug discovery.